Table 5.
Association between aPS/PT IgG antibody levels and APS clinical manifestations.
| Clinical parameter | Total = 103 n (%) | Median (CI 95%) if present | Median (CI 95%) if absent | p | Hodges–Lehmann shift (95% CI) |
|---|---|---|---|---|---|
| APS | 25 (24) | 11.5 (8.9–27.0) | 9.0 (7.7–11.6) | <0.01 | 3.5 (1.36–9.06) |
| Thrombosis | 34 (33) | 12.1 (8.4–20.3) | 9.2 (7.6–11.6) | 0.01 | 2.7 (0.67–7.37) |
| Pregnancy morbidity a | 16 (57) | 9.0 (7.6–15.0) | 13.4 (5.8–28.7) | 0.43 | -2.8 (-17.4–2.63) |
| SLE | 38 (37) | 12.3 (9.2–15.7) | 8.7 (8.0–10.2) | 0.06 | 2.5 (-0.11–5.34) |
| Triple positive | 20 (19) | 15.8 (10.2–96.3) | 8.8 (7.9–11.1) | <0.01 | 6.3 (2.5–17.1) |
| LA | 27/101 (27) | 12.3 (8.8–88.5) | 9.2 (7.7–11.5) | <0.01 | 3.2 (1.2–8.7) |
| GAPSS > 9 | 32/85 (38) | 3.3 (9.2 – 27.0) | 8.7 (7.6 – 11.3) | <0.01 | 4.6 (1.4–9.0) |
aData calculated on the total number of women who have had at least one pregnancy (n = 28).
APS, anti-phospholipid syndrome; SLE, systemic lupus erythematous; LA, lupus anticoagulant; GAPSS, Global Antiphospholipid Syndrome Score.
Bold means statistically significant values.